ORIGINAL COMMUNICATION



Prediction contribution of the cranial collateral circulation to the clinical and radiological outcome of ischemic stroke

Julian Conrad^{1,2} · Matthias Ertl^{2,3} · Meret H. Oltmanns⁴ · Peter zu Eulenburg^{2,5}

Received: 5 November 2019 / Revised: 13 March 2020 / Accepted: 16 March 2020 / Published online: 23 March 2020 © The Author(s) 2020

Abstract

Background and Aim The extent of penumbra tissue and outcome in stroke patients depend on the collateral cranial vasculature. To provide optimal individualized care for stroke patients in the emergency room setting we investigated the predictive capability of a stringent evaluation of the collateral vessels in ischemic stroke on clinical outcome and infarct size.

Methods We retrospectively studied uniform clinical and radiological data of 686 consecutive patients admitted to the emergency department with suspected acute ischemic stroke. Cranial collateral vasculature status was graded using the initial CT-angiography. Outcome was measured by mRS, NIHSS and final infarct size at hospital discharge. All data were used to build a linear regression model to predict the patients' outcome.

Results Univariate and multivariate analyses showed significant effects of the whole brain collateral vessel score on all outcome variables. Atherosclerosis and piale collateral status were associated with the final infarct volume (FIV). Atherosclerosis and age were associated with the NIHSS at discharge. The presence of atherosclerosis, glucose level on admission and age were associated with the mRS at discharge. The multivariate models were able to predict 29% of the variance of the mRS at discharge, 24% of the variance in FIV and 17% of the variance of the NIHSS at discharge. The whole brain collateral status and the presence of atherosclerosis were the most relevant predictors for the clinical and radiological outcome.

Conclusion The whole brain collateral vasculature status is clearly associated with clinical and radiological outcome but in a multivariate model seems not sufficiently predictive for FIV, mRS and NIHSS outcome at discharge in non-preselected patients admitted to the emergency department with ischemic stroke.

Keywords Stroke · Collaterals · CT-angiography · Ischemic · Score

Julian Conrad and Matthias Ertl contributed equally to this work.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00415-020-09798-0) contains supplementary material, which is available to authorized users.

☑ Julian Conrad julian.conrad@med.uni-muenchen.de

- ¹ Department of Neurology, LMU Munich, Marchioninistr.15, 81377 Munich, Germany
- ² German Center for Vertigo and Balance Disorders (DSGZ), LMU Munich, Munich, Germany
- ³ Department of Psychology, University of Bern, Bern, Switzerland
- ⁴ Department of Neuroradiology, Johannes Gutenberg-University, Mainz, Germany
- ⁵ Institute for Neuroradiology, LMU Munich, Munich, Germany

Introduction

In ischemic stroke artery occlusion leads to the hypoperfusion of the subsequent areas within the territory of the occluded vessel. If perfusion is less than 10 mL/100 g/min, nerve cells are irreversibly damaged within minutes [1]. If cerebral blood flow is partially reduced nerve cells cease to function but are still structurally intact and are considered potentially salvable tissue which makes them the target of thrombolytic therapy [2]. Various studies have shown that patients with good collateral status have larger ischemic penumbra, smaller infarct size and better outcome following thrombolysis and recanalization procedures [3, 4].

We aimed to predict clinical outcome on the grounds of the general collateral vessel status on the initial CT-angiography to develop an overall score to identify patients with a low collateral status that might profit from a more aggressive interventional therapy thereby facilitating a more personalized care of stroke patients in general. CT-angiography was chosen because it is fast, easily applicable, widely available and does not require additional time-consuming image processing and reflects general medical practice.

Methods

Patients

We retrospectively studied the clinical and radiological data of 686 patients that were admitted to the tertiary referral center with an acute stroke and obtained a full radiological work-up [native CT, supra-aortal CT angiography (CTA) and a dedicated follow-up examination (cranial MRI or CT)] to quantify the final lesion size and location of the ischemic stroke (excluded: n = 156; data quality, n = 69; alternative diagnosis, n = 87, final analysis n = 530).

Predictor-variables

The entire cranial collateral vasculature status of the patients was evaluated by applying an in-house scoring sheet to the initial CT-angiography. All vessels were graded by one experienced clinician who was blinded for the other data and diagnosis at the time of evaluation (Table 1).

For the comprehensive arterial vasculature status score of the brain the left and right sides were added together to obtain one value per vessel assuming that atherosclerotic changes are evenly distributed in both hemispheres. The scores of the anterior cerebral artery (ACA-), middle (MCA-), posterior (PCA-) segments were also summed up but an additional weighting factor was introduced as atherosclerosis located more proximal in the course of the vessel would produce a more devastating effect on clinical outcome. The ACAsegments were calculated as $ACA = 2 \times A1 + A2$ while the other two were calculated as $MCA = 4 \times M1 + 2 \times M2 + M3$ and $PCA = 4 \times P1 + 2 \times P2 + P3$. The segments of the internal carotid artery were summarized in one ICA factor.

Relevant co-factors such as age, sex, atherosclerosis, infections, nicotine abuse and statin consumption, symptom onset, time to door and time to treatment were included. Atherosclerosis was recorded if CT angiography showed intravascular calcifications or hypodense plaques attached to the arterial wall. The applied intervention (none, iv thrombolysis, arterial thrombolysis or bridging lysis in combination with thrombectomy) and the infarct region were examined as well.

Outcome-variables

Final infarct size, National Institutes of Health Stroke Scale Score (NIHSS), and modified Ranking Scale (mRS) at the

 Table 1 Grading score for the affected vascular territories

VA, BAS, PCA, Pcom, ICA, ACA, Acom, MCA:
- 4: occluded
- 3: visible stenosis
- 2: hypoplastic
- 1: diameter variations
0: not assessable
1: normal
PICA, AICA, SCA, ophthalmic artery, medial meningeal artery:
1: assessable
0: not assessable
Piale arteries cortical:
0: 0–8 pial arteries visible
1: 9–11 pial arteries visible
2: > 11 piale arteries visible
Piale cerebellar arteries:
0: not visible / not assessable
1:<3 piale arteries visible
2:>2 piale arteries visible

VA vertebral artery, BAS basilar artery, PCA posterior cerebral artery, Pcom posterior communicating artery, ICA internal carotid artery, ACA anterior cerebral artery, Acom anterior communicating artery, MCA middle cerebral artery, PICA posterior inferior cerebellar artery, AICA anterior inferior cerebellar artery, SCA superior cerebellar artery

time of discharge were used as dedicated outcome variables (median 8 days). The infarct size was manually measured based on the high resolution CT or diffusion-weighted MR images at least 48 h after symptom onset.

Modelling

The data analysis and statistical modeling were performed using SPSS (Version 23.0.0.0, Armonk, NY, IBM Corp.). To test the effect of risk factors, demographic variables, collateral status and treatment on functional outcome univariate models were computed for each of the outcome variables (Cramers' V, χ^2 tests for metric variables, continuous variables were tested using Pearson's r). To predict the outcome of the three variables linear regression models were applied. In a second analysis step, we used a MANOVA approach to account for possible interactions of the dependent variables. Initially, the entire dataset was analyzed using all available variables as predictors. In a second step, only MCA territory strokes and different stroke volumes were considered.

Standard protocol approvals and patient consents

The study was performed in accordance with the 1964 Declaration of Helsinki and was approved by the local ethics committee. Written consent for data usage was obtained from all patients.

Data availability

The dataset is not publicly available but can be obtained from the corresponding authors on reasonable request.

Results

Predictor-variables

Demographic data are shown in Table 2, the distribution of vascular territories among the 530 patients is shown in Fig. 1d. In 91 patients the diagnosis was later changed clinically to transient ischemic attack (TIA).

Outcome-variables

The median infarct volume (FIV) was 2.76 ml (median 1.94 ml), for the distribution of FIV across the patient population see Table 2. Of all patients, 3.2% were evaluated within the first hour of symptom onset. In 16.4% (87) of the patients the exact time of symptom onset could not be determined (Fig. 1a, b). A third of the patients (32.2%, n=171) received iv thrombolysis with rt-PA, another 32% of the investigated cohort was treated with either intraarterial thrombolysis or in combination with thrombectomy (n=3) or applying a bridging lysis regimen and thrombectomy (n=9). More than half of the patients (55.1%, n=292) did not receive any acute intervention.

The median NIHSS at onset was 6.0 and 1 at the time of discharge from the hospital. The initial mRS was 3.0 and 2.0 for the follow-up measurement at discharge.

The correlation between the mRS and the NIHSS was 0.634 (p < 0.001) and the correlation between mRS and infarct size was 0.622 (p < 0.001). The correlation coefficient of the NIHSS with infarct volume was 0.541 (p < 0.001).

Univariate analysis

Univariate analysis showed an effect for the presence of atherosclerosis in the CTA on admission, elevated blood glucose level on admission, piale collateral status, baseline NIHSS and therapy on the FIV. Atherosclerosis, age, treatment, age and stroke severity were significantly related to NIHSS score at discharge. Finally, atherosclerosis, glucose level on admission, age and stroke severity were significantly associated with the mRS. The whole brain vessel score was correlated with all three outcome variables in univariate analysis when considering all patients as well as the subgroup of MCA territory strokes only. (Table 3). No significant effect on the three outcome variables was found for collateral status in severe stroke (i.e., NIHSS > 17, n = 36).

Regression models

We first estimated a linear regression model using whole brain collateral status score, piale collateral score, atherosclerosis, elevated blood glucose level on admission, statine medication, infectious constellation (clinical or laboratory tests), history of smoking, age, sex and the type of applied treatment as predictor variables. This first model including the whole dataset explained 29.0% of the variance when predicting the mRS, 24% when predicting the FIV and 17% when predicting the NIHSS. The predictive capacity changed only moderately when including only strokes in the MCA territory or medium volume strokes (15-100 ml). The whole brain collateral status was the strongest predictor for all outcome measures. Apart from the collateral status, the presence of atherosclerosis was predictive of the NIHSS at discharge in all models, while an elevated glucose level on admission and age were predictive of the mRS at discharge when considering the whole data set and medium to large (non-malignant) volume strokes (FIV 15-100 ml). We attempted to analyze the subgroup of malignant profile / severe strokes (i.e., infarct volume > 100 ml, NIHSS > 17), however, this analysis did not yield reliable enough results due to the small number of cases in the sub-analysis (see Table 4) [5].

In addition, we reanalyzed the data using a MANOVA approach using the same variables as predictors of functional and radiological outcome (see Fig. 2). Using this complementary multivariate analysis approach we could confirm our findings from the original linear regression models. An analysis of medium size and malignant profile strokes was not methodologically possible with this approach. The model was performing best when using mRs at discharge as dedicated outcome variable while it was least predictive of the FIV when considering the whole data set as well as MCA territory strokes only.

Discussion

We aimed to introduce a simple grading algorithm for collateral vessels in the emergency room setting using the conventional diagnostic measures that are widely available for everyday clinical practice.

On a univariate level we could replicate findings that whole brain collateral vessel status as well as risk factors such as atherosclerosis, elevated glucose levels on admission as well as interventional treatment are related to the functional and radiological outcome of the patients [6–10]. This is of particular interest since we used a novel scoring method to evaluate the collateral vessel status of the whole brain. Table 2Demographics,cofactors and treatmentoutcomes

Age	65.7 years (±15.0; range 19–90 years)		
Gender			
Female	207 (39.1%)		
Male	323 (60.9%)		
NIHSS admission (median, IQR)	6.0 (8.0)		
NIHSS discharge (median, IQR)	1 (4.0)		
mRS admission (median, IQR)	3.0 (2.0)		
mRS discharge (median, IQR)	2.0 (2.0)		
Infarct volume (median, IQR)	1.94 ml (27.8)		
Atherosclerosis (n/%)	175 (33%)		
Smoking $(n/\%)$	207 (39.1%)		
Elevated glucose level on admission $(n/\%)$	28 (5.3%)		
Infection $(n/\%)$	13 (2.5%)		
Intervention $(n/\%)$			
IV thrombolysis	171 (32.2%)		
IA thrombolysis (±bridging)	32 (6%)		
Mechanical thrombectomy	11 (2%)		
No intervention	292 (55.1%)		
Final infarct volume (FIV)			
<15 ml	66.00%		
15–50 ml	11.70%		
50–100 ml	8.90%		
>100 ml	13.30%		
Treatment outcomes (median, IQR)	FIV (ml)	NIHSS	mRS
IV thrombolysis	5.4 (56.68)	2.0 (6.0)	2.0 (3.0)
IA thrombolysis (±bridging)	77.1 (223.4)	3.0 (12.0)	4.5 (2.5)
Mechanical thrombectomy	36.6 (55.35)	5 (.5)	2.0 (4.0)
No intervention	0.56 (8.04)	1 (4.0)	1.0 (3.0)
MCA territory only			
LVOS	105 (31.0%, 90 M1 segment, 15 ICA)		
Final infarct volume (FIV)			
<15 ml	61.70%		
15–50 ml	13.00%		
50–100 ml	9.00%		
>100 ml	16.20%		
Treatment outcomes (median, IQR)	FIV (ml)	NIHSS	mRS
IV thrombolysis	4.86 (59.3)	2 (6.0)	2 (2.3)
IA thrombolysis (\pm bridging)	113.81 (222.4)	5.5 (13.3)	4.0 (3.0)
Mechanical thrombectomy	35.4 (44.5)	5 (6.0)	2 (3.3)
No intervention	1.2 (22.8)	1.5 (5.0)	2.0 (3.0)

However, using a regression model our data show in a large sample of acute stroke patients that the status of the collateral vessels on a whole brain level using CTA is not reliably predictive of the final infarct size, mRs and NIHSS on a multivariate level. This was true for both multivariate analysis approaches used in our study. The predictive capacity of the model was moderately increased when including only strokes in the territory of the MCA. However, with the described model we were able to account for 29% of the variance at most.

Our data shed a new light on several clinical trials that demonstrated the importance of collateral status on clinical outcome using different grading techniques to evaluate patients' collateral status [11–15]. Most of these studies only included patients with large artery occlusion that were potentially eligible for thrombectomy whereas in our study, median infarct volume and the rate of clinically severe stroke (i.e., NIHSS > 17) was rather small representing an actual natural cohort. There is also great variability in the methods and grading systems used to quantify collateral perfusion



Fig. 1 a-c show the effect of symptom duration before getting to the emergency department on FIV; NIHSS and mRS. **d** Relative distribution of the affected vascular territories

that has to be accounted for [4, 16]. In summary, our cohort is far more heterogenous and closer to a real-life scenario because we included all patients admitted with the suspicion of an ischemic stroke/TIA [4, 16-18].

We conclude that a whole-brain vessel score for all patients regardless of the vascular territory involved or the location of the occluded vessel does not appear to help to prospectively identify patients for a more aggressive therapeutic approach. It seems that only the dedicated territorial evaluation concerning the exact location of the ischemic lesion and its surrounding vessels during actual interventional angiography or a combination with perfusion measures would be suitable to better predict the clinical outcome on a multivariate level. It might be possible that grading of the vascular collateral status is more helpful in selected patients with large artery occlusion and/ or severe strokes. This question should be addressed in future studies.

It is noteworthy that in our dataset sometimes over 50% of the variance for the respective model could not be explained by any of our variables. This indicates that lot more than the obvious patient inherent factors, such as age and gender or comorbidity, as documented by statin consumption, smoking or infectious complications during the hospital stay and the status of the collateral vasculature seem to contribute to the final infarct size and persisting clinical deficit. Factors that might change the magnitude of cerebral collateral blood flow (genetic or preexisting conditions, actual hemodynamic situation during the CT-angiography) that are not evident at the time of arrival in the emergency department might also play into the relatively low amount of variance explained by our model in general [1, 19].

However, even in the pooled analysis of multiple large multicenter trials of therapeutic interventions on stroke outcome which demonstrated the effect of mechanical thrombectomy on clinical outcome, only 12% of the clinical effect was explained by final infarct volume. Therefore, apart from the unknowns described above this seems to be an inherent limitation of the statistical methods used in our and the aforementioned study to predict outcome based on values of estimation of FIV [20].

Future studies in larger populations should emphasize the role of vascular territory involved and classify the pathophysiological mechanism (large artery occlusion vs. lacunar) in more detail. This has been shown to be effective for large artery atherosclerosis vs. cardioembolic strokes and the effect of adjacent collateral vessels compared with the contralateral non-affected hemisphere. A prediction approach using regional weights should then allow for more precise prediction models than a whole brain analysis since the presence of collateral vasculature is known to differ between spatially distinct regions of the brain [15, 21]. This could help us reach a personalized medicine model in stroke when predicting final infarct size

Table 3	Univariate analysis of co factors and	collateral status on FIV, NIHSS a	and mRS at discharge (Cramers'	V, Pearson's $r, p < 0.05$)
---------	---------------------------------------	-----------------------------------	--------------------------------	------------------------------

FIV	All patients		MCA territory only		
	Effect size	Sig	Effect size	Sig	
	Cramers V	р	Cramers V	р	
Atherosclerosis	0.122	0.0094	0.12	0.3	
Infection	0.1	0.232	0.088	0.618	
Glucose	0.18	0.003	0.177	0.03	
Statine	0.066	0.638	0.107	0.471	
Male sex	0.053	0.751	0.186	0.019	
Smoking	0.032	0.937	0.157	0.096	
C C	Pearson's r	р	Pearson's r	р	
Age	0.39	0.39	0.011	0.853	
Whole brain collateral vessel score	-0.459	< 0.0001	-0.38	< 0.0001	
Piale collaterals only	-0.209	< 0.0001	-0.251	< 0.0001	
Baseline NIHSS	0.59	< 0.0001	0.615	< 0.0001	
NIHSS discharge	0.541	< 0.0001	0.423	< 0.0001	
mRS discharge	0.622	< 0.0001	0.556	< 0.0001	
	Cramers V	n	Cramers V	р	
Therapy	0.414	<pre>// / / / / / / / / / / / / / / / / / /</pre>	0.436	<pre>// / / / / / / / / / / / / / / / / / /</pre>	
NIHSS discharge	Cramers V	<i>p</i>	Cramers V	р	
Atherosclerosis	0.151	0.008	0.156	0.034	
Infection	0.059	0.474	0.093	0.298	
Glucose	0.25	< 0.0001	0.221	0.001	
Statine	0.04	0.722	0.076	0.449	
Male sex	0.02	0.914	0.016	0.963	
Smoking	0.039	0.957	0.054	0.672	
C	Pearson's r	р	Pearson's r	р	
Age	0.125	0.01	0.108	0.074	
Whole brain collateral vessel score	-0.305	< 0.0001	-0.33	< 0.0001	
Piale collaterals only	0.037	0.46	-0.1	0.109	
Baseline NIHSS	0.677	< 0.0001	0.638	< 0.0001	
mRS discharge	0.559	< 0.0001	0.539	< 0.0001	
	Cramers V	n	Cramers V	<i>p</i>	
Therapy	0.2	0.029	0.23	0.063	
mRS discharge	Cramers V	p	Cramers V	p	
Atherosclerosis	0.217	< 0.0001	0.25	< 0.0001	
Infection	0.05	0.319	-0.27	0.665	
Glucose	0.122	0.014	0.122	0.052	
Statine	0.054	0.284	-0.059	0.349	
Male sex	0.01	0.839	0.033	0.596	
Smoking	0.099	0.139	0.005	0.924	
C	Pearson's r	р	Pearson's r	р	
Age	0.208	< 0.0001	0.235	r < 0.0001	
Whole brain collateral vessel score	-0.446	< 0.0001	-0.436	< 0.0001	
Piale collaterals only	-0.035	0.5	-0.133	0.04	
Baseline NIHSS	0.636	< 0.0001	0.56	< 0.0001	
NIHSS discharge	0.586	< 0.0001	0.539	< 0.0001	
FIV	0.264	< 0.0001	0.387	< 0.0001	
			Cramers V	n	
Therapy	0.225	< 0.0001	0.177	P 0.09	
PJ	0.220	×0.0001	0.177	0.07	

 Table 4
 Multivariate linear regression models predicting the variance of FIV, NIHSS and mRS at discharge (p<0.05)</th>

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	All territories	Final infarct volume (FIV)				NIHSS discharge				mRS discharge			
Whole brain vessel score -6.91 -5.62 -0.30 -7.19 <0.001		t	р	ß		t		ß		t	р	ß	
Piale cultarenis only -1.94 0.53 0.58 -0.57 0.39 -0.02 0.10 -0.09 0.925 0.01 Athenosclerosis -0.01 0.56 0.34 0.24 0.11 -0.09 0.925 -0.01 Statine -0.01 0.56 -0.01 -0.05 -0.03 -1.36 0.17 -0.06 Statine -0.61 0.53 -0.61 1.07 0.05 -1.36 0.07 1.74 -0.06 Statine -0.61 0.53 -0.61 1.07 0.05 -1.36 0.07 0.07 Age 0.33 0.742 0.33 -0.61 0.05 -1.36 0.76 0.01 -1.15 Male sex 1.63 0.067 1.83 0.02 0.03 -1.15 0.36 0.72 0.00 0.24 It thromoblysis (bridging 4.77 <0.001	Whole brain vessel score	-6.91	< 0.001	-6.91		-5.62		-0.30		-7.19	< 0.001	-0.37	
Atheroscleroxis -0.5 0.45 0.11 -000 0.26 -0.01 Glacoc level 0.34 0.738 0.34 0.738 0.34 0.738 0.01 0.12 1.36 0.173 0.07 Smoking 1.76 0.79 1.76 0.51 0.02 1.76 0.08 0.738 0.07 <	Piale collaterals only	-1.94	0.053	-1.94		-0.39		-0.02		0.10	0.923	0.01	
Glacose level0.340.380.342.470.122.130.0340.10Statine-0.010.996-0.01-0.65-0.03-1.360.174-0.06Infection-0.610.543-0.611.070.051.760.080.07Infection-0.610.543-0.611.070.051.760.0600.24Male sex1.330.4671.830.020.01-0.660.720.000.24Vichomobolysis1.67V.0014.772.020.01-0.360.720.02-Ithomobolysis4.77v.0014.772.720.13-1.150.260.050.24-Mathemobolysis1.0412.355v.0000.241.2351.150.260.0000.24-MCA only1.2355v.0010.272.720.131-1.150.260.050.25Mathemobolysis1.0412.355v.001-0.271.231.0000.001.150.260.0000.24Mathemobolysis-1.230.30-0.13-0.29-0.02-6.68v.001-0.38Mathemobolysis-1.240.33-0.07-0.27-0.39-0.170.770.360.12-Mathemobolysis-1.150.570.37-0.39-0.02-0.68-0.00-0.08-Statime0.570.570.37<	Atherosclerosis	-0.55	0.58	-0.55		2.04		0.11		-0.09	0.926	-0.01	
Sating -0.01 0.079 -0.01 0.65 -0.03 -1.36 0.74 -0.03 Smoking -7.6 0.079 1.76 0.61 0.51 0.02 1.37 0.073 0.77 0.07 Age 0.33 0.42 0.33 0.22 0.06 4.71 0.06 0.36 7.7 0.001 2.43 0.061 2.43 0.061 2.43 0.061 2.43 0.061 2.43 0.061 2.43 0.061 2.43 0.061 2.43 0.061 2.43 0.061 2.43 0.061 2.43 0.061 2.43 0.061 2.43 0.061 0.02 2.43 0.001 0.12 2.33 0.001 0.29 Toronbetony -1.34 0.25 0.001 0.17 0.02 0.01 0.12 2.33 0.001 0.294 0.001 0.12 2.33 0.001 0.294 0.001	Glucose level	0.34	0.738	0.34		2.47		0.12		2.13	0.034	0.10	
Sinkking 1.76 0.079 1.76 0.51 0.02 1.37 0.173 0.07 Infection -0.61 0.53 -0.61 1.07 0.05 1.76 0.08 0.08 1 Age 0.33 0.742 0.33 1.22 0.06 4.71 <0.001	Statine	-0.01	0.996	-0.01		-0.65		-0.03		-1.36	0.174	-0.06	
Infection -0.61 0.543 -0.61 1.07 0.05 1.76 0.08 0.08 Age 0.33 0.742 0.33 1.22 0.06 4.71 0.001 2.62 0.01 0.36 0.72 0.001 0.20 0.01 0.36 0.72 0.001 0.71 0.001 4.77 0.001 4.77 0.001 4.77 0.001 4.77 0.001 4.77 0.001 4.77 0.001 4.77 0.001 1.115 0.26 0.051 0.12 Drombectom -0.37 0.711 -0.7 0.22 0.131 1.115 0.26 0.051 0.27 0.03 0.01 0.12 0.031 </td <td>Smoking</td> <td>1.76</td> <td>0.079</td> <td>1.76</td> <td></td> <td>0.51</td> <td></td> <td>0.02</td> <td></td> <td>1.37</td> <td>0.173</td> <td>0.07</td> <td></td>	Smoking	1.76	0.079	1.76		0.51		0.02		1.37	0.173	0.07	
Age 0.33 0.742 0.33 1.22 0.06 4.71 < 6.001 0.24 Male sex 1.83 0.07 1.83 0.20 0.01 0.33 2.43 0.016 0.12 0.02 K1 thrombolysis (bridging 4.77 < 0.00 4.77 0.00 0.65 0.03 2.43 0.016 0.10 2.43 0.016 0.10 2.43 0.016 0.12 2.43 0.016 0.051 0.10 0.10 0.001 0.27 0.27 0.001 0.27 0.001 0.27 0.001 0.28 2.43 0.016 0.12 2.43 0.016 0.17 1.25 0.26 0.005 0.001 0.29 0.02 0.001 0.29 0.02 0.03	Infection	-0.61	0.543	-0.61		1.07		0.05		1.76	0.08	0.08	
Male sex 1.83 0.067 1.83 0.20 0.01 0.36 0.72 0.02 IV thrombolysis (bridging) 4.77 <0.001	Age	0.33	0.742	0.33		1.22		0.06		4.71	< 0.001	0.24	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Male sex	1.83	0.067	1.83		0.20		0.01		0.36	0.72	0.02	
IA hrombolysis (bridging) 4.77 <0.001 4.77 <0.001 4.77 <0.001 4.77 <0.001 0.05 1.96 0.051 0.10 Thrombectomy -0.37 0.711 -0.37 0.711 -0.37 0.711 -0.37 0.711 -0.37 0.711 -0.37 0.71 12.391 df p dg P 2.33 2.0001 0.29 MCA only Final infart volume (FIV) p β r r p β r r p β r	IV thrombolysis	2.62	0.009	2.62		0.65		0.03		2.43	0.016	0.12	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	IA thrombolysis (bridging)	4.77	< 0.001	4.77		0.90		0.05		1.96	0.051	0.10	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Thrombectomy	-0.37	0.711	-0.37		2.72		0.131		1.115	0.266	0.052	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Overall model	F	df	n	adi R ²	F	df	n	adi R ²	F	df	n	adi R ²
$ \begin{tabular}{ c c c c c c c c c c c c c c c c c c c$		11.04	12,355	<pre>// < 0.0001</pre>	0.24	7.224	12,361	<pre>// < 0.0001</pre>	0.17	12.519	12,333	<pre>// < 0.0001</pre>	0.29
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	MCA only	Final ir	nfarct volu	me (FIV)		NIHSS	5 discharg	<u>ge</u>		mRS d	ischarge		
		t	р	β		t		ß		t	р	ß	
Piale collaterals only -2.13 0.03 -0.13 -0.39 -0.02 -0.68 0.497 -0.04 Athcrosclerosis -0.22 0.83 -0.01 2.04 0.11 0.07 0.942 0.00 Glucose level 1.15 0.25 0.07 2.47 0.12 2.11 0.036 0.12 Statine 0.57 0.35 -0.65 -0.03 -1.07 0.257 0.36 0.716 0.02 Statine -1.11 0.27 -0.07 1.07 0.05 0.85 0.366 0.057 Male sex 2.98 <0.001 1.122 0.06 4.72 <0.001 0.31 Male sex 2.98 <0.001 0.23 0.90 0.05 0.33 -0.02 0.01 0.78 0.437 0.05 Ithrombolysis (bridging) 3.68 <0.001 0.23 0.90 0.05 0.78 0.437 0.05 Overall model F df p $adj R^2$ F	WholeBrain vessel score	-4.49	< 0.001	-0.29		- 5.62		-0.30		-6	< 0.001	-0.38	
Atherosclerosis -0.22 0.83 -0.01 2.04 0.11 0.07 0.942 0.00 Glucose level 1.15 0.25 0.07 2.47 0.12 2.11 0.036 0.12 Statine 0.57 0.57 0.03 -0.65 -0.03 -1.07 0.287 -0.06 Smoking 1.91 0.06 0.11 0.51 0.02 0.36 0.716 0.27 Age 0.21 0.83 0.01 1.22 0.06 4.72 <0.001 0.31 Male sex 2.98 <0.001 0.18 0.20 0.01 0.78 0.437 0.05 Ithrombolysis (bridging) 3.68 <0.001 0.23 0.90 0.5 0.78 0.437 0.05 Ithrombolysis (bridging) -0.61 0.541 -0.04 2.715 0.131 -0.04 0.68 -0.02 Overall model 0.593 10.26 0.805 na 0.81^2 $I0.23$ 0.01 0.23	Piale collaterals only	-2.13	0.03	-0.13		-0.39		-0.02		-0.68	0.497	-0.04	
Glucose level 1.15 0.25 0.07 2.47 0.12 2.11 0.036 0.12 Statine 0.57 0.57 0.03 -0.65 -0.03 -1.07 0.287 -0.06 Smoking 1.91 0.06 0.11 0.51 0.02 0.36 0.716 0.02 Infection -1.11 0.27 -0.07 1.07 0.05 0.85 0.396 0.05 Age 0.21 0.83 0.01 1.22 0.06 4.72 $<$ 0.001 0.31 Male sex 2.98 $<$ 0.001 0.18 0.20 0.01 0.78 0.437 0.05 IV thrombolysis 1.14 0.26 0.07 0.65 0.03 -0.38 0.705 -0.02 Ithrombolysis (bridging) 3.68 $<$ 0.001 0.23 0.90 0.05 0.78 0.437 0.05 Thrombectomy -0.61 0.541 -0.04 2.715 0.131 -0.04 0.968 -0.002 Overall model 0.593 10.26 0.805 na	Atherosclerosis	-0.22	0.83	-0.01		2.04		0.11		0.07	0.942	0.00	
Statine 0.57 0.57 0.03 -0.65 -0.03 -1.07 0.287 -0.06 Smoking 1.91 0.06 0.11 0.51 0.02 0.36 0.716 0.02 Infection -1.11 0.27 -0.07 1.07 0.05 0.88 0.396 0.05 Age 0.21 0.83 0.01 1.22 0.06 4.72 $<$ 0.001 0.31 Male sex 2.98 $<$ 0.001 0.18 0.20 0.01 0.78 0.437 0.05 IV thrombolysis 1.14 0.26 0.07 0.65 0.03 -0.38 0.705 -0.02 IV thrombolysis (bridging) 3.68 $<$ 0.001 0.23 0.90 0.05 0.78 0.437 0.05 Overall model F df p adj R^2 F df p adj R^2 F df p adj R^2 Overall model 0.593 10.26 0.805 na 0.813 10.23 0.61	Glucose level	1.15	0.25	0.07		2.47		0.12		2.11	0.036	0.12	
Simoking 1.91 0.06 0.11 0.51 0.02 0.36 0.716 0.02 Infection -1.11 0.27 -0.07 1.07 0.05 0.85 0.396 0.05 Age 0.21 0.83 0.01 1.22 0.06 4.72 <0.00	Statine	0.57	0.57	0.03		-0.65		-0.03		-1.07	0.287	-0.06	
Infection -1.11 0.27 -0.07 1.07 0.05 0.85 0.396 0.05 Age 0.21 0.83 0.01 1.22 0.06 4.72 <0.001 0.31 Male sex 2.98 <0.001 0.18 0.20 0.01 0.78 0.437 0.05 IV thrombolysis 1.14 0.26 0.07 0.65 0.03 -0.38 0.75 -0.02 IA thrombolysis (bridging) 3.68 <0.001 0.23 0.90 0.05 0.78 0.437 0.05 Inombectomy -0.61 0.541 -0.04 2.715 0.131 -0.04 0.968 -0.002 Overall model F df p adj R^2 F df p adj R^2 Malignant (FIV > 100 ml) NIHSS discharge mRS discharge mRS discharge R^2 df p adj R^2 Medium FIV (15-100 ml) NIHSS discharge p β df p gg </td <td>Smoking</td> <td>1.91</td> <td>0.06</td> <td>0.11</td> <td></td> <td>0.51</td> <td></td> <td>0.02</td> <td></td> <td>0.36</td> <td>0.716</td> <td>0.02</td> <td></td>	Smoking	1.91	0.06	0.11		0.51		0.02		0.36	0.716	0.02	
Age 0.21 0.83 0.01 1.22 0.06 4.72 <0.01 0.31 Male sex 2.98 <0.001	Infection	- 1.11	0.27	-0.07		1.07		0.05		0.85	0.396	0.05	
Wale sex 2.98 <0.001 0.18 0.20 0.01 0.78 0.437 0.05 IV thrombolysis 1.14 0.26 0.07 0.65 0.03 -0.38 0.705 -0.02 IA thrombolysis (bridging) 3.68 <0.001	Age	0.21	0.83	0.01		1.22		0.06		4.72	< 0.001	0.31	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Male sex	2.98	< 0.001	0.18		0.20		0.01		0.78	0.437	0.05	
Number of the second method metho	IV thrombolysis	1.14	0.26	0.07		0.65		0.03		-0.38	0.705	-0.02	
Initial of the gring bit of the gring bit of the transformation of transformation of the transformat	IA thrombolysis (bridging)	3.68	< 0.001	0.23		0.90		0.05		0.78	0.437	0.05	
Antimized my of M of M </td <td>Thrombectomy</td> <td>-0.61</td> <td>0 541</td> <td>-0.04</td> <td></td> <td>2 715</td> <td></td> <td>0.03</td> <td></td> <td>-0.04</td> <td>0.968</td> <td>-0.002</td> <td></td>	Thrombectomy	-0.61	0 541	-0.04		2 715		0.03		-0.04	0.968	-0.002	
6.25 12,228 <0.001 0.21 7.24 12,361 <0.001 0.17 8.571 12,215 <0.001 0.29 Malignant (FIV > 100 ml) NIHSS discharge \overline{F} df p adj R^2 \overline{F} df p adj R^2 Overall model 0.593 10,26 0.805 na 0.813 10,23 0.619 na Medium FIV (15–100 ml) NIHSS discharge mRS discharge mRS discharge mRS discharge t p β WholeBrain vessel score -5.62 <0.001 -0.30 -7.19 <0.001 -0.37 Piale collaterals only -0.39 0.70 -0.02 0.1 0.923 0.01 Atherosclerosis 2.04 0.04 0.11 -0.09 0.926 -0.01 Glucose level 2.47 0.01 0.12 2.13 0.034 0.10 Statine -0.65 0.52 -0.03 -1.36 0.174 -0.06 Smoking 0.51 0.61 0.02 1.37 0.173 0.07 <	Overall model	F	df	n	adi R ²	E.715	df	n	adi R ²	F	df	n	adi R ²
Malignant (FIV > 100 ml) NIHSS discharge mRS discharge mRS discharge \overline{F} df p $adj R^2$ \overline{F} df p $adj R^2$ Overall model 0.593 10,26 0.805 na 0.813 10,23 0.619 na Medium FIV (15–100 ml) NIHSS discharge mRS discharge mRS discharge t p β WholeBrain vessel score -5.62 <0.001 -0.30 -7.19 <0.001 -0.37 Piale collaterals only -0.39 0.70 -0.02 0.1 0.923 0.01 Glucose level 2.47 0.01 0.12 2.13 0.034 0.10 Statine -0.65 0.52 -0.03 -1.36 0.174 -0.06 Smoking 0.51 0.61 0.02 1.37 0.173 0.07 Infection 1.07 0.29 0.05 1.76 0.08 0.08 Age 1.22 <td>o veran moder</td> <td>6.25</td> <td>12,228</td> <td><i>P</i> < 0.001</td> <td>0.21</td> <td>7.224</td> <td>12,361</td> <td><i>P</i> < 0.001</td> <td>0.17</td> <td>8.571</td> <td>12,215</td> <td><i>P</i> < 0.001</td> <td>0.29</td>	o veran moder	6.25	12,228	<i>P</i> < 0.001	0.21	7.224	12,361	<i>P</i> < 0.001	0.17	8.571	12,215	<i>P</i> < 0.001	0.29
F df p $adj R^2$ F df p $adj R^2$ Overall model 0.593 10,26 0.805 na 0.813 10,23 0.619 na Medium FIV (15–100 ml) NIHSS discharge mRS discharge mRS discharge mRS discharge r p β r r p β r <td< td=""><td>Malignant (FIV > 100 ml)</td><td colspan="3">NIHSS discharge</td><td></td><td colspan="3">mRS disch</td><td>RS discha</td><td>urge</td><td></td><td></td><td></td></td<>	Malignant (FIV > 100 ml)	NIHSS discharge				mRS disch			RS discha	urge			
Overall model 0.593 $10,26$ 0.805 na 0.813 $10,23$ 0.619 na Medium FIV (15–100 ml) NIHSS discharge mRS discharge mRS discharge t p β WholeBrain vessel score -5.62 <0.001 -0.30 -7.19 <0.001 -0.37 Piale collaterals only -0.39 0.70 -0.02 0.1 0.923 0.01 Atherosclerosis 2.04 0.04 0.11 -0.09 0.926 -0.01 Glucose level 2.47 0.01 0.12 2.13 0.034 0.10 Statine -0.65 0.52 -0.03 -1.36 0.174 -0.06 Smoking 0.51 0.61 0.02 1.37 0.173 0.07 Infection 1.07 0.29 0.05 1.76 0.08 0.08 Age 1.22 0.20 0.84 0.01 0.26 0.72 0.02 <		\overline{F}		df	р		adj R ²	\overline{F}		df	р		adj R ²
Medium FIV (15-100 ml) NIHSS discharge mRS discharge mRS discharge p β WholeBrain vessel score -5.62 <0.001	Overall model	0.	593	10,26	0.805		na	0.813		10,23	0.619		na
t p β t p β WholeBrain vessel score -5.62 <0.001 -0.30 -7.19 <0.001 -0.37 Piale collaterals only -0.39 0.70 -0.02 0.1 0.923 0.01 Atherosclerosis 2.04 0.04 0.11 -0.09 0.926 -0.01 Glucose level 2.47 0.01 0.12 2.13 0.034 0.10 Statine -0.65 0.52 -0.03 -1.36 0.174 -0.06 Smoking 0.51 0.61 0.02 1.37 0.173 0.07 Infection 1.07 0.29 0.05 1.76 0.08 0.08 Age 1.22 0.22 0.06 4.71 <0.001 0.24	Medium FIV (15–100 ml)	NIHSS discharge				mRS discha			irge				
WholeBrain vessel score -5.62 < 0.001 -0.30 -7.19 < 0.001 -0.37 Piale collaterals only -0.39 0.70 -0.02 0.1 0.923 0.01 Atherosclerosis 2.04 0.04 0.11 -0.09 0.926 -0.01 Glucose level 2.47 0.01 0.12 2.13 0.034 0.10 Statine -0.65 0.52 -0.03 -1.36 0.174 -0.06 Smoking 0.51 0.61 0.02 1.37 0.173 0.07 Infection 1.07 0.29 0.05 1.76 0.08 0.08 Age 1.22 0.20 0.84 0.01 0.26 0.72 0.02		t		р	ß			t		р	ß		
Piale collaterals only -0.39 0.70 -0.02 0.1 0.923 0.01 Atherosclerosis 2.04 0.04 0.11 -0.09 0.926 -0.01 Glucose level 2.47 0.01 0.12 2.13 0.034 0.10 Statine -0.65 0.52 -0.03 -1.36 0.174 -0.06 Smoking 0.51 0.61 0.02 1.37 0.173 0.07 Infection 1.07 0.29 0.05 1.76 0.08 0.08 Age 1.22 0.20 0.84 0.01 0.26 0.72 0.02	WholeBrain vessel score	- :	5.62	< 0.001	-0.	.30		-7.19		< 0.001	-0.37		
Atherosclerosis 2.04 0.04 0.11 -0.09 0.926 -0.01 Glucose level 2.47 0.01 0.12 2.13 0.034 0.10 Statine -0.65 0.52 -0.03 -1.36 0.174 -0.06 Smoking 0.51 0.61 0.02 1.37 0.173 0.07 Infection 1.07 0.29 0.05 1.76 0.08 0.08 Age 1.22 0.22 0.06 4.71 <0.001 0.24	Piale collaterals only	_(0.39	0.70	-0.	02		0.1		0.923	0.0)1	
Glucose level 2.47 0.01 0.12 2.13 0.034 0.10 Statine -0.65 0.52 -0.03 -1.36 0.174 -0.06 Smoking 0.51 0.61 0.02 1.37 0.173 0.07 Infection 1.07 0.29 0.05 1.76 0.08 0.08 Age 1.22 0.22 0.06 4.71 <0.001	Atherosclerosis	2.0	04	0.04	0.11			-0	.09	0.926	- (0.01	
Statine -0.65 0.52 -0.03 -1.36 0.174 -0.06 Smoking 0.51 0.61 0.02 1.37 0.173 0.07 Infection 1.07 0.29 0.05 1.76 0.08 0.08 Age 1.22 0.22 0.06 4.71 <0.001	Glucose level	2.4	47	0.01	0.12	2		2.1	3	0.034	0.1	0	
Smoking 0.51 0.61 0.02 1.37 0.173 0.07 Infection 1.07 0.29 0.05 1.76 0.08 0.08 Age 1.22 0.22 0.06 4.71 <0.001	Statine	_(0.65	0.52	-0.	03		-1	.36	0.174	-().06	
Infection 1.07 0.29 0.05 1.76 0.08 0.08 Age 1.22 0.22 0.06 4.71 <0.001 0.24 Male sex 0.20 0.84 0.01 0.36 0.72 0.02	Smoking	0.5	51	0.61	0.02	2		1.3	7	0.173	0.0)7	
Age 1.22 0.22 0.06 4.71 <0.001 0.24 Male sex 0.20 0.84 0.01 0.36 0.72 0.02	Infection	1.0	07	0.29	0.05	5		1.7	6	0.08	0.0)8	
Malo sox 0.20 0.84 0.01 0.26 0.72 0.02	Age	1.2	22	0.22	0.06	ó		4.7	1	< 0.001	0.2	24	
0.20 0.04 0.01 0.30 0.72 0.02	Male sex	0.2	20	0.84	0.01			0.3	6	0.72	0.0)2	
IV thrombolysis 0.65 0.52 0.03 2.43 0.016 0.12	IV thrombolysis	0.6	65	0.52	0.03	;		2.4	3	0.016	0.1	2	

Table 4 (continued)

Medium FIV (15–100 ml)	NIHSS di	ischarge			mRS discharge			
	t	р	ß		t	р	ß	
IA thrombolysis (bridging)	0.9	0.367	0.046		1.96	0.051	0.10	
Thrombectomy	2.72	0.007	0.131		1.12	0.266	0.052	
Overall model	F	df	р	adj R ²	F	df	р	adj R ²
	7.224	12,361	< 0.001	0.17	12.519	12,333	< 0.001	0.29

Fig. 2 Multivariate analysis of variance (MANOVA) and its effect on the three outcome variables including all data and MCA territory only



and more importantly clinical outcome by evaluating the status of the collateral vasculature of the brain at event onset.

Acknowledgements Open Access funding provided by Projekt DEAL. This work contains data and analyses that stem from the doctoral thesis of Meret Oltmanns.

Compliance with ethical standards

Conflicts of interest Julian Conrad, Matthias Ertl, Meret H. Oltmanns and Peter zu Eulenburg reports no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

- 1. Shuaib A, Butcher K, Mohammad AA, Saqqur M et al (2011) Collateral blood vessels in acute ischaemic stroke: a potential therapeutic target. Lancet Neurol 10:909–921
- Davis S, Donnan GA (2014) The ischemic penumbra: imaging, selection and outcome. Cerebrovasc Dis 38:59–72
- Campbell BC, Christensen S, Tress BM, Churilov L, EPITHET Investigators et al (2013) Failure of collateral blood flow is associated with infarct growth in ischemic stroke. J Cereb Blood Flow Metab 33:1168–1172
- Jadhav AP, Diener HC, Bonafe A, Pereira VM et al (2017) Correlation between clinical outcomes and baseline CT and CT angiographic findings in the SWIFT PRIME trial. Am J Neuroradiol 38(12):2270–2276
- Mlynash M, Lansberg MG, De Silva DA, Lee J, Christensen S, Straka M, on behalf of the DEFUSE-EPITHET Investigators et al (2011) Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled dataset. Stroke 42(5):1270–1275
- Lima FO, Furie KL, Silva GS, Lev MH, Camargo EC, Singhal AB et al (2010) The pattern of leptomeningeal collaterals on CT angiography is a strong predictor of long-term functional outcome in stroke patients with large vessel intracranial occlusion. Stroke 41(10):2316–2322
- Menon BK, Smith EE, Coutts SB, Welsh DG, Faber JE, Goyal M et al (2013) Leptomeningeal collaterals are associated with modifiable metabolic risk factors. Ann Neurol 74(2):241–248

- Liebeskind DS, Jahan R, Nogueira RG, Zaidat OO, Saver JL (2014) Impact of collateralson successful revascularization in solitaire FR with the intention for thrombec-tomy. Stroke 45:2036–2040
- 9. Berkhemer OA, Jansen IG, Beumer D et al (2016) Collateral status on baseline com-puted tomographic angiography and intra-arterial treatment effect in patients with proximal anterior circulation stroke. Stroke 47:768–776
- Nordmeyer H, Webering N, Chapot R, Hadisurya J, Heddier M, Stracke P et al (2017) The association between collateral status, recanalization and long term outcome in stroke patients treated with stent retrievers—are there indications not to perform thrombectomy based on CT angiography? J Neuroradiol 44(3):217–222
- Miteff F, Levi CR, Bateman GA, Spratt N et al (2009) The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. Brain 132(8):2231–2238
- Maas MB, Lev MH, Ay H, Singhal AB et al (2009) Collateral vessels on CT angiography predict outcome in acute ischemic stroke. Stroke 40(9):3001–3005
- Menon BK, Smith EE, Modi J, Patel SK et al (2011) Regional leptomeningeal score on CT angiography predicts clinical and imaging outcomes in patients with acute anterior circulation occlusions. Am J Neuroradiol 32(9):1640–1645
- 14. Makris N, Chamard L, Mikkelsen IK, Hermier M et al (2019) Acute reperfusion without recanalization: serial assessment of

collaterals within 6 h of using perfusion-weighted magnetic resonance imaging. J Cereb Blood Flow Metab 39:1–9

- Menon BK, O'Brien B, Bivard A, Spratt NJ et al (2013) Assessment of leptomeningeal collaterals using dynamic CT angiography in patients with acute ischemic stroke. J Cereb Blood Flow Metab 33:365–371
- Goyal M, Demchuk AM, Menon BK, Eesa M, ESCAPE Trial Investigators et al (2015) Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 72:1019–1030
- 17. Menon BK, Qazi E, Nambiar V, Foster LD et al (2015) Differential effect of baseline CTA collaterals on clinical outcome in patients enrolled in the IMS-III trial. Stroke 46:1239–1244
- Marks MP, Lansberg MG, Mlynash M, Olivot JM et al (2014) Effect of collateral blood flow on patients undergoing endovascular therapy for acute ischemic stroke. Stroke 45:1035–1039
- Epstein SE, Lassance-Soares RM, Faber JE, Burnett MS (2012) Effects of aging on the collateral circulation, and therapeutic implications. Circulation 125:3211–3219
- Boers AMM, Jansen IGH, Brown S, Lingsma HF, Beenen LFM, Devlin TG et al (2019) Mediation of the relationship between endovascular therapy and functional outcome by follow-up infarct volume in patients. JAMA Neurol 762:194–202
- Rebello LC, Bouslama M, Haussen DC, Grossberg JA et al (2017) Stroke etiology and collaterals: atheroembolic strokes have greater collateral recruitment than cardioembolic strokes. Eur J Neurol 24(6):762–767